From what 1 stock analysts predict, the share price for Entera Bio Ltd (ENTX) might decrease by 100% in the next year. This is based on a 12-month average estimation for ENTX. Price targets go from $ to $. The majority of stock analysts believe ENTX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
ENTX is a stock in Healthcare which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Maxim Group and on the lower end ENTX is forecasted to be $ by from Maxim Group.
These are the latest 20 analyst ratings of ENTX.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Nov 11, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Oct 7, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Sep 27, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 12, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 5, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | May 14, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | May 13, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Maintains | Apr 2, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Dec 11, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Sep 13, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Sep 11, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | May 8, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Apr 4, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Mar 28, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Initiates | Sep 6, 2022 |
Kalpit Patel B. Riley Securities | Buy | $5 | Maintains | Jul 19, 2022 |
B. Riley Securities | Buy | Initiates | Jun 16, 2021 | |
Aegis Capital | Buy | Initiates | Mar 22, 2021 | |
Maxim Group | Buy | Initiates | Aug 3, 2018 |
When did it IPO
2018
Staff Count
17
Country
Israel
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Miranda J. Toledano M.B.A.
Market Cap
$61.5M
In 2023, ENTX generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that ENTX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Entera Bio Ltd. (NASDAQ: ENTX) announced its financial results and business updates for Q3 2024, reporting significant developments in oral peptides and small therapeutic proteins.
Why It Matters - Entera Bio's financial results and business updates may indicate performance trends and growth potential, influencing stock valuation and investment decisions.
Summary - Entera Bio Ltd. (ENTX) reported a quarterly loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.05 loss.
Why It Matters - Entera Bio's larger-than-expected quarterly loss may indicate operational challenges, potentially impacting investor confidence and stock performance.
Summary - Entera Bio and OPKO Health announced positive topline PK/PD results from their collaboration on an oral dual agonist for obesity, utilizing OPKO's OXM analog and Entera's N-Tabโข technology.
Why It Matters - The collaboration may lead to a groundbreaking obesity treatment, potentially increasing market share and revenues for Entera Bio and OPKO, influencing their stock performance positively.
Summary - Entera and OPKO Health report positive pharmacokinetic/pharmacodynamic results in their research for the first oral dual agonist GLP-1/glucagon peptide.
Why It Matters - Positive PK/PD results from Entera and OPKO Health suggest potential breakthroughs in obesity and diabetes treatments, possibly increasing market value and attracting investor interest.
Summary - Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have been assessed for their performance relative to their sector in the current year. Further details on metrics were not provided.
Why It Matters - Comparative performance metrics indicate how Entera Bio Ltd. and argenex SE are faring against their peers, influencing investment decisions based on market trends and company viability.
Summary - Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have shown performance results compared to their sector in 2023, as detailed in the report.
Why It Matters - Performance comparisons reveal how ENTX and AKBA are faring against their sector, indicating investor sentiment, potential growth, or risks that may influence investment decisions.